May 24th – 26th 2018

Workshop & Symposium

„Tumor Immunology meets Oncology XIV“

Institute of Medical Immunology
Prof. Dr. Barbara Seliger

WELCOME TO HALLE (SAALE)
Dear colleagues and friends,

once again it is a great pleasure to welcoming you in Halle for our meeting „Tumor immunology meets oncology (TIMO XIV)“, which started 14 years ago and has steadily grown over the years. This conference provides a platform of basic immunologic and translational research. It is a forum for preclinical researchers and clinicians involved in tumor immunology and immunotherapy to address and discuss emerging topics in this field immunotherapy.

The meeting focusses on immune escape mechanisms, immune tolerance, immune metabolism, tumor microenvironment and anti-tumoral immune responses. Since immunotherapies have recently been successfully implemented for the treatment of many cancers, there is an urgent need to increase therapy efficacy and reprogramming immune escape mechanisms. In this context, novel immunotherapeutic strategies and the development of resistances to these therapies and biomarkers for monitoring, immune responses will be discussed.

This meeting attracts an extraordinary group of national and international scientists and clinicians. Furthermore, it represents the main activity of the working group “Tumor immunology” of the German Society of Immunology with the aim to understand anti-tumor immune responses, to treat different tumor entities with distinct immunotherapeutic approaches and also to promote young scientists/clinicians to present their own work.

We would like to welcome you to Halle and wish you all an exciting workshop and symposium. In addition, we hope that you have a pleasant stay and will leave with impressions of the beauty and hospitality of the city, with a bunch of novel insights for your own basic and/ or translational research and with new friends.

I express my gratitude to all who were involved in the organization of this event and gratefully acknowledge our sponsors for supporting this meeting as well as the participants for joining us.
General information

Registration packages are ready for pick-up at the TIMO registration desk located in the lobby of Building 6, Lecture Hall at the University Hospital Kroellwitz. Faculties are required to upload their presentation no later than half an hour before the session starts in the lecture hall.

The poster session will be held at the 24th of May 2018 from 06.00 to 07.30 p.m. and offers an opportunity for continued network and provides education in a relaxed atmosphere, where attendees can interact with poster presenters one by one. In addition, during lunch of the 25th of May 2018 there will be time for poster viewing.
Workshop program „Tumor immunology”

**Date:** 24th of May 2018  
**Venue:** University Hospital Halle, Building 6, Lecture Hall  
Ernst-Grube-Straße 40, 06120 Halle

12.00 – 12.15 p.m.  
Introduction (Barbara Seliger)

**NEWS OF TUMOR IMMUNOLOGY**  
Chair: Dagmar Riemann (Halle)  
Marc Schmitz (Dresden)

12.15 – 12.30 p.m.  
The role of the NKG2D receptor and its ligands for immunosurveillance in ovarian cancer  
Nathalie Hoffmann (Marburg, GER)

12.30 – 12.45 p.m.  
IGF2BP1 promotes immune evasion in advanced stage ovarian cancer  
Nadine Bley (Halle, GER)

12.45 – 01.00 p.m.  
NF-κB activation triggers NK-cell stimulation by mono-cyte-derived dendritic cells  
Naomi Bosch (Erlangen, GER)

01.00 – 01.15 p.m.  
The role of education in the interaction between vaccine DC and NK cells  
Chiara Massa (Halle, GER)

01.15 – 01.30 p.m.  
Reactive species in immunogenic cancer cell death  
Sander Bekeschus (Greifswald, GER)

01.30 – 01.45 p.m.  
Impact of MCT4 deficiency on T cell function  
Christina Bruß (Regensburg, GER)

01.45 – 02.00 p.m.  
The impact of the tumor stroma and infiltrating immune cells in cancer microtissues  
Stefan Köck (Innsbruck, AUT)
02.00 – 02.15 p.m.
Live-cell assays for immune cell killing of 3D tumour spheroids
Annedore Respa (Hertfordshire, GBR)

02.15 – 02.30 p.m.
Natural Polymer X (NPX): A novel adjuvant for protein-based vaccination strategies
Anna dalla Pietà (Padova, ITA)

02.30 – 02.45 p.m.
Modifying melanoma immune microenvironment by heterologous prime-boost vaccination with adenovirus and modified vaccinia ankara virus vectors
Tetje van der Sluis (Magdeburg, GER)

02.45 – 03.00 p.m.
Increased TGF-β signaling facilitates an immune suppressive melanoma microenvironment in the context of immune-checkpoint inhibition
Stefanie Löffek (Essen, GER)

03.00 – 03.30 p.m. Coffee break

METHODS AND MORE NEWS
Chair: Elfriede Nößner (Munich)
Zelig Eshhar (Rehovot, ISR)

03.30 – 03.45 p.m.
Mass spectrometry-based identification of a naturally presented ROR1-derived epitope recognized by tumor-reactive CD8+ cytotoxic T cells
Falk Heidenreich (Dresden, GER)

03.45 – 04.00 p.m.
Integration of genomics and neoepitopes in clinical studies and cancer therapy
Peter Fasching (Erlangen, GER)

04.00 – 04.15 p.m.
Molecular characterisation on protein level of neuroblastoma and anti-PD1 treatment response biomarker profiling in melanoma
Ronny Schmidt (Heidelberg, GER)
04.15 – 04.30 p.m.
Assessment of gut microbiome and host inflammatory cytokines of metastatic melanoma patients in correlation to response to anti-PD-1 therapy
Erez Baruch (Tel Aviv, ISR)

04.30 – 04.45 p.m.
Development of a novel target module for retargeting of UniCAR T cells to sialyl-Tn expressing cancer cells
Liliana Loureiro (Dresden, GER)

04.45 – 05.00 p.m.
Type I IFN response in oncolytic virotherapy: a double edged sword
Janne Ruotsalainen (Magdeburg, GER)

05.00 – 05.15 p.m.
Tools for translational immune system research
Müge Akpinar (München, GER)

05.15 – 05.30 p.m.
The role of the circulating proteome in immunotherapy resistance
Heinrich Röder (Boulder, USA)

05.30 – 05.45 p.m.
An embryonic gene signature is associated with immune exclusion and poor outcome in immunotherapy treated patients
Ettai Markovits (Tel Aviv, ISR)

05.45 – 06.00 p.m.
Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients
Helen Angell (Essex, GBR)

Summary: Jörg Wischhusen (Würzburg)
Poster session „Tumor immunology“

Date: 24th of May 2018, 06.00 – 07.30 p.m.
Venue: University Hospital Halle, Building 6, Lobby
Ernst-Grube-Straße 40, 06120 Halle

POSTER SESSION
Chair: Doriana Fruci / Peter Fasching

1. Neoadjuvant radiochemotherapy increases the percentage of interferon-alpha-expressing plasmacytoid dendritic cells in rectal cancer
Rebekka Wehner (Dresden, GER)

2. Influence of bodyweight on receptor expression and cytotoxicity of primary human natural killer cells against obesity-associated cancers
Wiebke Naujoks (Halle, GER)

3. Identification of immune modulatory micro RNAs in tumors
Michael Friedrich (Halle, GER)

4. Myelodysplastic syndromes – the role of microRNAs in disease initiation, progression and immunological control
Andrea Kindermann (Halle, GER)

5. Correlation of immune cell infiltration with the MHC class I pathway and clinical relevance in oral squamous cell cancer
Claudia Wickenhauser (Halle, GER)

6. Size matters: CEACAM1-3S drives melanoma cells into NK cell-mediated cytolysis and enhances patients’ survival
Iris Helfrich (Essen, GER)

7. Optimization of end point PCR for the determination of ESR1, PGR and ERBB2 status in a resource limited settings: Ethiopian context
Zelalem Desalegn Woldeonbet (Addis Abeba, ETH)
8. Anti-proliferative efficacy of romidepsin, lapatinib and trametinib in breast cancer cell lines
   Meron Yohannes (Addis Abeba, ETH)

9. Identifying patients for combined Radio-Immuno-therapy - new frontiers and the „Halle approach“
   Christian Ostheimer (Halle, GER)

10. The costimulatory signaling domain in CAR-modified T effector cells influences their responsiveness to immunosuppression by regulatory T cells
    Alexandra Kegler (Dresden, GER)

11. Increasing apparent affinity of EGFR-directed target modules results in enhanced anti-tumor and diagnostic properties of the UniCAR system
    Susann Albert (Dresden, GER)

12. Influence of Histidine-tag on immunotherapeutic and diagnostic properties of anti-PSCA target modules
    Justyna Jureczek (Dresden, GER)

13. Different modes of modulation of MHC class I antigens in HER-2/neu expressing tumor cells
    Jürgen Bukur (Halle, GER)

14. Evolution of cross-resistance to CD8\(^+\) T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma
    Fang Zhao (Essen, GER)

15. The role of selenium for reversion of immune escape
    Claudia Lennicke (Halle, GER)

16. Age dependent Sirtuin expression in primary human T cells
    Georgiana Toma (Halle, GER)

17. Effect of selective Gq/11-inhibition on malignant melanoma
    Naveen Shridhar (Magdeburg, GER)
18. Decoding the complexity of Breast Cancer Biology – the Breast Cancer 360 expression panel
Christoph König (Hamburg, GER)

19. Characterization of innate immune infiltrate in patients with meningioma
Sara Magri (Padova, ITA)

20. Monitoring advanced NSCLC through plasma genotyping during immunotherapy: preliminary results
Andrea Boscolo Bragadin (Padova, ITA)

21. Immunomodulatory role of physical plasma-derived oxidants in malignant melanoma
Juliane Moritz (Greifswald, GER)

22. MHC class II Dextramers - A new tool for detection of antigen specific CD4+ T cells
Liselotte Brix, Bjarke E. Hansen (Copenhagen, DK)

23. Orf virus – a novel vaccine platform for infectious diseases and cancer
Alena Reguzova, Melanie Müller (Tübingen, GER)

24. Effect of sunitinib treatment on the immune cell repertoire of renal cell cancer patients
Barbara Seliger (Halle, GER)
Symposium program „Tumor immunology“

Date: 25th of May 2018
Venue: University Hospital Halle, Building 6, Lecture Hall
       Ernst-Grube-Straße 40, 06120 Halle

08.30 a.m.
Welcome and introduction
Dean of the Faculty: Michael Gekle
Organizer: Barbara Seliger

Session: Immune modulation and microenvironment
Chair: Samir Khleif/ Mary L. Disis

08.45 – 09.15 a.m.
Molecular programs defining tumor-specific T cell dysfunction
Andrea Schietinger (New York, USA)

09.15 – 09.45 a.m.
Immune microenvironment in neuroblastoma: clinical and therapeutic relevance
Doriana Fruci (Rome, ITA)

09.45 – 10.15 a.m.
Biology and clinical relevance of neutrophils and MDSC in tumor host
Sven Brandau (Essen, GER)

10.15 – 11.00 a.m. Coffee break

Session: Immune escape and immune modulation
Chair: Sven Brandau / Rolf Kiessling

11.00 – 11.30 a.m.
Renal cancer: bridging metabolism and immunology
Matthias Schwab (Stuttgart, GER)

11.30 – 12.00 p.m.
Complex interplay between T cell metabolism and function
Ramon Klein Geltink (Freiburg, GER)
12.00 – 12.30 p.m.
Tumor immune escape – from microRNAs to extracellular matrix
Barbara Seliger (Halle, GER)

12.30 – 01.45 p.m.
LUNCH BREAK AND POSTER VIEWING

Key note lecture
Chair: Barbara Seliger

01.45 – 02.30 p.m.
Tumor and host factors controlling anti-tumor immuno-
ity and immunotherapy efficacy
Thomas Gajewski (Chicago, USA)

Session: News and views of CAR T cell therapy
Chair: Zelig Eshhar / Diana Dudziak

02.30 – 03.00 p.m.
Choice of optimal T cell subset and implementation of safeguards for adoptive T cell therapy
Dirk Busch (Munich, GER)

03.00 – 03.30 p.m.
TIL based adoptive T cell therapy in solid cancer
Inge M. Svane (Herlev, DK)

03.30 – 03.45 p.m.
T cell receptor gene therapy of cancer for new patient groups
Wolfgang Uckert (Berlin, GER)

03.45 – 04.15 p.m. Coffee break
Session: Immune microenvironment and therapeutic potential
Chair: Matthias Schwab / Tanja de Gruijl

04.15 – 04.30 p.m.
NK cells affect tumor metastasis via structural editing of primary tumors
Batya Isaacson (Jerusalem, ISR)

04.30 – 05.00 p.m.
Human dendritic cell subpopulations in steady state and inflammation
Diana Dudziak (Erlangen, GER)

05.00 – 05.30 p.m.
Breast cancer immune-landscape
Guiseppe Curigliano (Milan, ITA)

05.30 – 06.00 p.m.
HLA alleles and immune infiltrates in prostate and breast cancer as prognostic biomarkers
Costas Baxevanis (Athens, GRC)
**Session: Novel immunotherapeutic strategies**
Chair: Inge M. Svane/Thomas Gajewski

08.30 – 09.00 a.m.
Unlocking the therapeutic potential of tumor-draining lymph nodes
Tanja de Gruijl (Amsterdam, NL)

09.00 – 9.30 a.m.
Combining TIL therapy and DC vaccination of advanced malignant melanoma
Rolf Kiessling (Stockholm, SWE)

09.30 – 10.00 a.m.
Vaccines targeting oncogenic driver proteins
Mary L. Disis (Seattle, USA)

10.00 – 10.30 a.m.
The next generation of oncolytic virus immunotherapy
Howard Kaufmann (Boston, USA)

10.30 – 11.00 a.m. **Coffee break**

**Session: Combination therapy**
Chair: Howard Kaufman / Costas Baxevanis

11.00 – 11.30 a.m.
Combination treatments to modulate the microenvironment and boost tumor immunity
Sjoerd H. van der Burg (Leiden, NL)

11.30 – 12.00 p.m.
Combination immunotherapy, a new science in medicine
Samir Khleif (Washington, USA)
12.00 – 12.30 p.m.
Epigenetic immuno-sequencing in the clinic: initial results from the NIBIT-M4 study
Michele Maio (Siena, ITA)

12.30 – 12.45 p.m.
Wrap up and closing remarks
REGISTRATION FEE:

150 € - payable until 21st of April 2018 or cash at the registration desk - **Vouchers are required for registration.** MLU members will be charged for 50 €, students for free

*Registration can be waived in special cases (Please bring in your MLU/UKH ID card)*

**Bank name:**
Deutsche Apotheker- und Aerztebank
IBAN: DE46300606011008814171
SWIFT code: DAAEDEDD
reason for payment: name, reg. fee TIMO XII

**SYMPOSIUM SECRETARY:**

Maria Heise
Institute of Medical Immunology
Martin Luther University Halle-Wittenberg
Magdeburger Straße 2, 06097 Halle (Saale)
Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055
e-mail: immunologie@uk-halle.de

The Medical Association of Saxony-Anhalt credits this educational activity with 7 points (workshop) and 12 points (symposium). You will receive a certificate of attendance on site at the registration desk.
WE THANK OUR SPONSORS:

AstraZeneca GmbH (1.500€), Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb (3.000€), CDDF (Cancer Drug Development Forum, 2.500€), Celgene GmbH (2.000€), Cellex PT, City of Halle, Deutsche Forschungsgesellschaft (DFG), German Society for Immunology (DGfI), Epiontis GmbH, Essen BioScience Ltd, Fluidigm, GEMoaB GmbH, Immudex USA, Janssen Cilag GmbH (1.000€), Lipocalyx GmbH, Miltenyi Biotec GmbH, Roche Pharma AG (1.500€), Sarstedt, Sciomics GmbH, SERVA GmbH, siTOOLS BioTech GmbH, Society for Immunotherapy of Cancer (SITC), Thermo Fisher Scientific, QIAGEN GmbH
CONFERENCE VENUE:
University Hospital Halle
Ernst-Grube-Strasse 40; 06120 Halle
Building 6, Lecture Hall

Airport or main train station transportation:
Various taxi companies service the airport Leipzig or the main train station Halle. A cab ride costs approx. 45 € from the airport to the clinic and from the train station to the Conference venue approx. 8 €. In addition, public train service is available from the airport to Halle (every 30 min.).

From the main train station in Halle you can take the tram no. 4 or 5, direction Heide or Kroellwitz.

PARKING INFORMATION:
Several parking facilities are located next to the Ernst-Grube-Street. Please follow the sign „Parkplatz Universitätssklinik“.

PHOTOS:
Photos by © Michael Hoetzel, DGPh
in cooperation with the

DGfI
German Society
for Immunology

and

SITC
Society for Immunotherapy of Cancer

Institute of Medical Immunology
Prof. Dr. Barbara Seliger
Director of FOCIS Center of Excellence
Martin-Luther-University Halle-Wittenberg
Medical Faculty
Magdeburger Straße 2
06112 Halle (Saale)
Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055
e-mail: immunologie@uk-halle.de